Browse more peptide research, methods and limitations.
Analysis of semaglutide effects on kidney function across different baseline levels confirms renal benefits regardless of starting kidney status.
Apperloo, Ellen M; Cherney, David Z I; Kuhlman, Anja Birk; Mann, Johannes F E; Rasmussen, Søren; Rossing, Peter; Tuttle, Katherine R; Vrhnjak, Blaz; Heerspink, Hiddo J L · Meta Analysis
Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
Apperloo, Ellen M; Gorriz, Jose L; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas; van Beek, André P; Verhave, Jacobien; Ahmed, Sofia B; Schmieder, Roland E; Wanner, Christoph; Cherney, David Z I; Jongs, Niels; Heerspink, Hiddo J L · RCT
Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
Apperloo, Ellen M; Tuttle, Katherine R; Pavo, Imre; Haupt, Axel; Taylor, Rebecca; Wiese, Russell J; Hemmingway, Andrea; Cherney, David Z I; Sattar, Naveed; Heerspink, Hiddo J L · Meta Analysis
Development of a risk score for BNP ≥100 pg/mL enables prediction of elevated natriuretic peptide levels using clinical variables before blood testing.
Arafa, Ahmed; Kato, Yuka; Matsumoto, Chisa; Khairan, Paramita; Maeda, Saori; Kokubo, Yoshihiro · Cohort
ProBNP and estimated mature BNP from 12 hours to 5 days post-AMI, and cGMP from immediately post-intervention to 3 days, were independent predictors of left ventricular reverse remodeling.
Arai, Marina; Asaumi, Yasuhide; Honda, Satoshi; Ogata, Soshiro; Kiyoshige, Eri; Nakao, Kazuhiro; Miura, Hiroyuki; Morita, Yoshiaki; Nakashima, Takahiro; Murai, Kota; Iwai, Takamasa; Sawada, Kenichiro; Matama, Hideo; Fujino, Masashi; Takahama, Hiroyuki; Yoneda, Shuichi; Takagi, Kensuke; Otsuka, Fumiyuki; Kataoka, Yu; Nishimura, Kunihiro; Noguchi, Teruo; Minamino, Naoto; Yasuda, Satoshi · Cohort
Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefits of GLP-1/GIP dual agonism alongside metabolic improvements.
Arai, Taeang; Atsukawa, Masanori; Nagao, Chikako; Yamada, Zento; Rokugo, Takahiro; Suzuki, Kenta; Kitamura, Michika; Higashi, Tetsuyuki; Koyano, Kaori; Hasegawa, Yuta; Kawano, Tadamichi; Ono, Hiroki; Yoshida, Yuji; Okubo, Tomomi; Hayama, Korenobu; Nakagawa-Iwashita, Ai; Itokawa, Norio; Kondo, Chisa; Nagao, Mototsugu; Iwabu, Masato; Iwakiri, Katsuhiko · Cohort
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Aranishi, Toshihiko; Igarashi, Ataru; Hara, Kazuo; Osumili, Beatrice; Cai, Zhihong; Mizogaki, Aska; Sato, Manaka; Takeuchi, Masakazu; Minghetti, Alice; Hunt, Barnaby; Kadowaki, Takashi · Review
Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.
Aranäs, Cajsa; Caffrey, Antonia; Edvardsson, Christian E; Schmidt, Heath D; Jerlhag, Elisabet · Animal Study
Combined pharmacotherapy including GLP-1 drugs produced synergistic-like decreases in alcohol intake, supporting multi-target approaches to alcohol use disorder.
Aranäs, Cajsa; Caffrey, Antonia; Edvardsson, Christian E; Vestlund, Jesper; Schmidt, Heath D; Jerlhag, Elisabet · Animal Study
Novel electrochemiluminescence sensing technology for BNP detection achieves enhanced sensitivity for natriuretic peptide measurement in heart failure diagnostics.
Arathy, B K; Abraham, Merin K; Indongo, Geneva; Rajeevan, Greeshma; Dhahir, Dheyaa Mohammed; George, Sony · In Vitro
Perineural botulinum toxin injection for post-traumatic headache management showed effectiveness, leveraging the peptide toxin's neuromodulatory properties for pain relief.
Arce Gálvez, L; Mancera Álzate, J M · Case Series
Comprehensive proteomic analysis of scorpion venom identifies cancer-fighting peptide candidates through systematic characterization of venom peptide diversity.
Arcos, Stephanie Santos Suehiro; Aguiar, Mariana Ramos da Cunha; Oliveira, Júlia de; Silva, Matheus Ramos da; Pimentel, Isabela de Oliveira Cavalcante; Dos Anjos, Nicolas Gamboa; Machado, Gustavo Henrique Rohr Souza; Evangelista, Kimberly Borges; Portaro, Fernanda Calheta Vieira; Iwai, Leo Kei · Review
Analysis of weight reduction over time in tirzepatide-treated participants shows early response patterns predict long-term weight loss success.
Ard, Jamy; Lee, Clare J; Gudzune, Kimberly; Addison, Brandi; Lingvay, Ildiko; Cao, Dachuang; Mast, Casey J; Stefanski, Adam; Falcon, Beverly; Mojdami, Donna · RCT
Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
Argoff, Charles; Khan, Fawad A; Herzog, Steven P; Smith, Ryan M; Soni-Brahmbhatt, Seema; Asher, Divya; Awad, Susanne F; Grossman, S Wald; Patel, Foram; Buse, Dawn C · Cohort
Review explores the gut-brain axis in type 1 diabetes and obesity, examining how gut peptides including GLP-1 and GIP may influence T1D pathophysiology.
Argyrakopoulou, Georgia; Gitsi, Evdoxia; Dalamaga, Maria; Kokkinos, Alexander · Review
Review of obesity pharmacotherapy effects on body composition examines how GLP-1 and related drugs affect muscle mass, fat distribution, and bone density during weight loss.
Argyrakopoulou, Georgia; Gitsi, Evdoxia; Konstantinidou, Sofia K; Kokkinos, Alexander · Review
Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
Arif, Atia; Lama, Sanu; Singla, Bhavna; Singla, Shivam; Kumawat, Sunita; Tharwani, Anusha; Usman, Muhammad; Khalid, Hamna; Kanukollu, Venkata Madusudana Rao; Ekomwereren, Osatohanmwen; Khan, Shabir · Meta Analysis
Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
Aristizabal-Colorado, David; Vernaza Trujillo, David Alexander; Sierra Castillo, Santiago; Rivera Martinez, Wilfredo Antonio; Badiel, Marisol; Abreu Lomba, Alin · Cohort
Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
Aristizábal-Colorado, David; Corredor-Rengifo, David; Sierra-Castillo, Santiago; López-Corredor, Carolina; Vernaza-Trujillo, David-Alexander; Weir-Restrepo, Danilo; Izquierdo-Condoy, Juan S; Ortiz-Prado, Esteban; Rico-Fontalvo, Jorge; Gómez-Mesa, Juan-Esteban; Abreu-Lomba, Alin; Rivera-Martínez, Wilfredo-Antonio · Review
Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba; Al Musaimi, Othman · Review
Evaluation of GLP-1 drug effects on obstetric and perinatal outcomes provides critical safety data for the growing number of pregnancies exposed to these drugs.
Armstrong, Bruna Benigna Sales; Servidoni, Ana Clara Pimenta; Martin, Giovanna Cristina de Castro; Machado, Guilherme Franceschini; Amador, Wellgner Fernandes Oliveira; Yousif, Abdelrahman · Meta Analysis
Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
Armstrong, Matthew J; Okanoue, Takeshi; Sundby Palle, Mads; Sejling, Anne-Sophie; Tawfik, Mohamed; Roden, Michael · Meta Analysis
Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
Aroda, Vanita R; Jørgensen, Nils B; Kumar, Bharath; Lingvay, Ildiko; Laulund, Anne Sofie; Buse, John B · RCT
Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.
Aronne, Louis J; Horn, Deborah Bade; le Roux, Carel W; Ho, Wayne; Falcon, Beverly L; Gomez Valderas, Elisa; Das, Sagar; Lee, Clare J; Glass, Leonard C; Senyucel, Cagri; Dunn, Julia P · RCT
One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.
Arora, Prachi; Michalak, Wojciech; Zhao, Zhenxiang; Fiasconaro, Megan; Hong, Yu; Zhao, Xin; Ó Hartaigh, Bríain; Alvarez, Sara; Fitch, Angela · Cohort
Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
Arow, Ziad; Hornik-Lurie, Tzipi; Hilu, Ranin; Giladi, Ela; Arnson, Yoav; Vaknin-Assa, Hana; Assali, Abid; Pereg, David · Cohort
Review examines whether GLP-1 drugs can achieve true diabetes remission — sustained normalization of blood sugar without medication — and identifies who is most likely to achieve it.
Arpan; Singh, Navrajbir; Bali, Kusum; Singh, Tarundeep · Review
Systematic review of vascular responses to molecular migraine triggers including CGRP characterizes how these peptides cause blood vessel changes that produce migraine pain.
Arquizan, Robin; Melchior, Anna G; Christensen, Rune H; Al-Khazali, Haidar M; Ashina, Messoud; Ashina, Håkan · Meta Analysis
Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
Arredouani, Abdelilah · Review
Comprehensive review of GLP-1 drug efficacy and safety for weight management covers semaglutide, liraglutide, and emerging agents with real-world outcome data.
Arrowaili, Arief · Meta Analysis
Liraglutide protected against indomethacin-induced gastric damage in a preclinical model, adding gastroprotection to GLP-1 drug benefits through anti-inflammatory mechanisms.
Arslan, Huseyin Emre; Teksen, Yasemin; Ozatik, Orhan; Algin, Mustafa Cem · Animal Study
Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.
Arslanian, Silva; Gies, Inge; Goldman, Bryan; Karlsson, Tobias; Kelly, Aaron S; Skalshøi Kjær, Mette; Körner, Antje; Noureddin, Mazen; Wabitsch, Martin; Harder-Lauridsen, Nina M; Weghuber, Daniel · RCT
Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.
Arty, Fnu; Shreya, Devarashetty; Chaudhry, Aleeza; Sohini, Sarkar · Review
Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.
Arun, Amogh Jyothi; Darji, Bhavika; Baig, Madiha; Frishman, William H; Aronow, Wilbert S ·
Comparative study of neuropeptide function across species reveals how oxytocin, vasopressin, and other peptides regulate social behavior and the effects of social isolation.
Asahina, Kenta; Zelikowsky, Moriel ·
Discovery that VIP receptor VIPR2 must dimerize to bind vasoactive intestinal peptide reveals fundamental receptor biology with implications for VIP-based drug design.
Asano, Satoshi; Ozasa, Kairi; Uehara, Teru; Yokoyama, Rei; Nakazawa, Takanobu; Yanamoto, Souichi; Ago, Yukio ·
Analysis of clinical outcomes after hospitalization for acute coronary syndrome in GLP-1 drug users vs non-users evaluates whether prior GLP-1 therapy improves post-heart attack recovery.
Ascandar, Nameer; Boadu, Charles; Stepman, Gauthier; Skaf, George; Oyesanmi, Olugbenga; Omar, Sabry; Ali, Rias; Schandorf-Lartey, Michael ·
Rimegepant demonstrated efficacy for acute migraine treatment specifically in triptan-unsuitable adults, filling the treatment gap for this underserved patient population.
Ashina, Messoud; McAllister, Peter; Gaul, Charly; Leyva-Rendon, Adolfo; Ramirez, Luz M; Nalpas, Catherine; Thiry, Alexandra; Abraham, Lucy; Fountaine, Robert J; Fullerton, Terence ·
Long-term study confirms atogepant safety, efficacy, and functional improvement for migraine prevention, supporting sustained use of this oral CGRP antagonist.
Ashina, Sait; Ashina, Messoud; Holle-Lee, Dagny; Tassorelli, Cristina; Cho, Soo-Jin; He, Molly Yizeng; De Abreu Ferreira, Rosa; Gandhi, Pranav; Smith, Jonathan H; Pfleeger, Kimberly; Trugman, Joel M ·
Analysis of CGRP monoclonal antibody prescribing patterns reveals real-world usage trends, treatment sequences, and adherence in migraine prevention.
Ashina, Sait; Kim, Gilwan; Muenzel, E Jolanda; Buse, Dawn C; Zagar, Anthony J; Zakharyan, Armen; Shapiro, Robert E; Nicholson, Robert A; Pearlman, Eric M; Lipton, Richard B ·
Meta-analytic review of semaglutide safety and efficacy in T2D consolidates evidence across trials, confirming robust glucose-lowering and weight benefits with manageable safety.
Ashraf, Taimoor; Bai, Shevita; Kumar, Aashish; Subhash Sagar, Raja; Saloni, Fnu; Kumar, Anesh; Kumar, Rohet; Pahwani, Ashvin; Kumar, Vikash; Hassaan, Muhammad; Khatri, Govinda; Jabbar, Maheen; Deepak, Fnu; Abdella Yusuf, Salih ·
Review of migraine treatment advances covers anti-CGRP therapies, gepants, ditans, and emerging targets for comprehensive migraine management.
Ashraf, Usman; Goadsby, Peter J ·
Review explores GLP-1 receptor agonist potential impact in cancer therapy through anti-proliferative, anti-inflammatory, and metabolic mechanisms.
Aslam, Baseer; Bin Zafar, Muhammad D; Changez, Mah I Kan; Abdullah, Muhammad; Safwan, Muhammad; Qamar, Bisma; Shinwari, Abdullah; Rai, Sanjana ·
Comprehensive overview of opioid peptides covers their natural sources, molecular sequences, receptor specificity, and biological functions in pain and reward.
Asokan, Vishwadeep; Koundinya, Ariktha M; Aranganathan, V ·
Novel pH-responsive peptide-polymer hydrogel specifically disrupts bacterial biofilms in acidic infection environments, providing targeted antimicrobial peptide delivery.
Asokan-Sheeja, Haritha; Das, Debdatta; Nguyen, Jenny N; Xu, Jiazhu; Mukut, Md Tareque Hassan; Chau, Tung H; Buonomo, Joseph A; Hong, Yi; Dong, He ·
Review of synergistic potential between GLP-1 drugs and radiotherapy for brain cancer explores how metabolic peptide therapy could enhance radiation effectiveness.
Atasoy, Ozum; Anadol, Elvan; Yar Saglam, Atiye Seda; Akdemir, Eyub Yasar; Coskun, Yasemin Sengun; Atak, Ece; Dincer, Sefika; Usta, Duygu Deniz; Emniyet Sert, Aslı; Kaplanoglu, Gulnur Take; Guney, Yıldız ·
Randomized study of semaglutide effects on cognitive function in people with HIV finds potential neuroprotective benefits in this neurologically vulnerable population.
Atieh, Ornina; Daher, Joviane; Abboud, Marc; Wu, Qian; Sattar, Abdus; Baissary, Jhony; Koberssy, Ziad; Labbato, Danielle; Eckard, Allison Ross; McComsey, Grace A ·
Review of GLP-1 drug emerging therapeutic potential in psoriasis management covers anti-inflammatory mechanisms that may benefit this autoimmune skin disease.
Atiquzzaman, Nabiha; Razdolsky, Nicole; Parmar, Mayur S ·
Study of how structural modifications tune antimicrobial properties of peptide-mimicking compounds reveals design rules for optimizing synthetic antimicrobial peptides.
Attard, Samuel T; Aldilla, Vina R; Kuppusamy, Rajesh; Chen, Renxun; Black, David StC; Thordarson, Pall; Willcox, Mark D P; Kumar, Naresh ·
Systematic review of GLP-1 drug effects on mortality across conditions provides comprehensive evidence for their life-extending potential.
Au, Hezekiah C T; Zheng, Yang Jing; Le, Gia Han; Wong, Sabrina; Phan, Lee; Teopiz, Kayla M; Kwan, Angela T H; Rhee, Taeho Greg; Rosenblat, Joshua D; Ho, Roger; McIntyre, Roger S ·